PalamarJJFitzgeraldNDGrundyDJ, et al. (2022) Characteristics of poisonings involving ketamine in the United States, 2019-2021. J Psychopharmacol. Epub ahead of print 7 December 2022. DOI: 10.1177/02698811221140006.
2.
SzarmachJCubałaWJWłodarczykA, et al. (2021) Somatic comorbidities and cardiovascular safety in ketamine use for treatment-resistant depression. Medicina57: 274.
3.
WilkowskaAWłodarczykAGałuszko-WęgielnikM, et al. (2021) Intravenous ketamine infusions in treatment-resistant bipolar depression: An open-label naturalistic observational study. Neuropsychiatr Dis Treat17: 2637–2646.
4.
WłodarczykACubałaWJGałuszko-WęgielnikM, et al. (2021) Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression. Ther Adv Psychopharmacol11: 5. DOI: 10.1177/20451253211011021.
